N Engl J Med

Kidney Week 2024: How long do empagliflozin benefits persist in CKD patients?

November 1, 2024

Empagliflozin provides sustained benefits in patients with chronic kidney disease (CKD) even after discontinuation, the EMPA-KIDNEY posttrial period showed. These findings were shared at the American Society of Nephrology's Kidney Week meeting.

Patients with CKD (N = 6,609) were randomly assigned to receive either empagliflozin or placebo and were followed for a median of 2 years, with an additional 2-year post-trial follow-up for consenting participants (74%).

Key findings: In the post-trial period, the risk of primary outcome events (CV death or kidney disease progression) was 13% lower for the empagliflozin group compared with the placebo group (hazard ratio [HR], 0.87). In the combined active- and post-trial periods, kidney disease progression or CV death occurred in 26.2% of patients in the empagliflozin group and 30.3% in the placebo group (HR, 0.79). SGLT2 inhibitor usage was similar between the two groups during the post-trial period.

Source:

EMPA-KIDNEY Collaborative Group; et al. (2024, October 25). N Engl J Med. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. https://pubmed.ncbi.nlm.nih.gov/39453837/